Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)

• Published in: International journal of clinical oncology 2019-10, Vol.24 (10), p.1204-1213
• Main Authors: Sasaki, Shun, Oki, Eiji, Saeki, Hiroshi, Shimose, Takayuki, Sakamoto, Sanae, Hu, Qingjiang, Kudo, Kensuke, Tsuda, Yasuo, Nakashima, Yuichiro, Ando, Koji, Akagi, Yoshito, Kakeji, Yoshihiro, Baba, Hideo, Maehara, Yoshihiko
• Format: Article
• Language: English
• Subjects: Body mass index; Cancer Research; Chemotherapy; Clinical trials; Colorectal cancer; Colorectal carcinoma; Computed tomography; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Musculoskeletal system; Oncology; Patients; Prognosis; Sarcopenia; Skeletal muscle; Surgical Oncology
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-019-01460-8

Background Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference ( P